Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. Recent statistics from the American Cancer Society indicate that the incidence of MM is increasing. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) included in this issue address management of patients with solitary plasmacytoma and newly diagnosed MM.

  • 1

    SiegelRLMillerKDJemalA. Cancer statistics, 2015. CA Cancer J Clin2015;65:529.

  • 2

    BrennerHGondosAPulteD. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood2008;111:25212526.

    • Search Google Scholar
    • Export Citation
  • 3

    KumarSKRajkumarSVDispenzieriA. Improved survival in multiple myeloma and the impact of novel therapies. Blood2008;111:25162520.

  • 4

    PalumboAAndersonK. Multiple myeloma. N Engl J Med2011;364:10461060.

  • 5

    AndersonKC. Oncogenomics to target myeloma in the bone marrow microenvironment. Clin Cancer Res2011;17:12251233.

  • 6

    HideshimaTAndersonK. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer2002;2:927937.

  • 7

    DispenzieriAKyleRMerliniG. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia2009;23:215224.

    • Search Google Scholar
    • Export Citation
  • 8

    KuhnemundALiebischPBauchmullerK. ‘Light-chain escape-multiple myeloma’-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol2009;135:477484.

    • Search Google Scholar
    • Export Citation
  • 9

    DurieBGHarousseauJLMiguelJS. International uniform response criteria for multiple myeloma. Leukemia2006;20:14671473.

  • 10

    KyleRAGertzMAWitzigTE. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc2003;78:2133.

  • 11

    ShaughnessyJJacobsonJSawyerJ. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood2003;101:38493856.

    • Search Google Scholar
    • Export Citation
  • 12

    XiongWWuXStarnesS. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood2008;112:42354246.

    • Search Google Scholar
    • Export Citation
  • 13

    DrachJAckermannJFritzE. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood1998;92:802809.

    • Search Google Scholar
    • Export Citation
  • 14

    Avet-LoiseauHAttalMMoreauP. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood2007;109:34893495.

    • Search Google Scholar
    • Export Citation
  • 15

    GertzMALacyMQDispenzieriA. Clinical implications of t(11;14) (q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood2005;106:28372840.

    • Search Google Scholar
    • Export Citation
  • 16

    GutierrezNCCastellanosMVMartinML. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia2007;21:143150.

    • Search Google Scholar
    • Export Citation
  • 17

    RossFMAvet-LoiseauHAmeyeG. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica2012;97:12721277.

    • Search Google Scholar
    • Export Citation
  • 18

    Avet-LoiseauHMalardFCampionL. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?Blood2011;117:20092011.

    • Search Google Scholar
    • Export Citation
  • 19

    FonsecaRBloodERueM. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood2003;101:45694575.

  • 20

    NairBvan RheeFShaughnessyJDJr.. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood2010;115:41684173.

    • Search Google Scholar
    • Export Citation
  • 21

    DewaldGTherneauTLarsonD. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood2005;106:35533558.

    • Search Google Scholar
    • Export Citation
  • 22

    FonsecaRBarlogieBBatailleR. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res2004;64:15461558.

  • 23

    HanamuraIStewartJPHuangY. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood2006;108:17241732.

    • Search Google Scholar
    • Export Citation
  • 24

    CarrascoDRTononGHuangY. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell2006;9:313325.

    • Search Google Scholar
    • Export Citation
  • 25

    RosinolLCarrioABladeJ. Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. Br J Haematol2005;130:729732.

    • Search Google Scholar
    • Export Citation
  • 26

    DispenzieriARajkumarSVGertzMA. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc2007;82:323341.

    • Search Google Scholar
    • Export Citation
  • 27

    KumarSKMikhaelJRBuadiFK. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc2009;84:10951110.

    • Search Google Scholar
    • Export Citation
  • 28

    MoreauPAttalMGarbanF. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia2007;21:20202024.

    • Search Google Scholar
    • Export Citation
  • 29

    FonsecaRBergsagelPLDrachJ. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia2009;23:22102221.

    • Search Google Scholar
    • Export Citation
  • 30

    ZhouYBarlogieBShaughnessyJDJr.The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia2009;23:19411956.

    • Search Google Scholar
    • Export Citation
  • 31

    DecauxOLodeLMagrangeasF. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol2008;26:47984805.

    • Search Google Scholar
    • Export Citation
  • 32

    ShaughnessyJDJr.ZhanFBuringtonBE. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood2007;109:22762284.

    • Search Google Scholar
    • Export Citation
  • 33

    KuiperRBroylAde KnegtY. A gene expression signature for high-risk multiple myeloma. Leukemia2012;26:24062413.

  • 34

    MoulopoulosLADimopoulosMAWeberD. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol1993;11:13111315.

    • Search Google Scholar
    • Export Citation
  • 35

    ZamagniECavoM. The role of imaging techniques in the management of multiple myeloma. Br J Haematol2012;159:499513.

  • 36

    DurieBWaxmanAD'AgnoloAWilliamsCM. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med2002;43:14571463.

  • 37

    SchirrmeisterHBommerMBuckAK. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging2002;29:361366.

    • Search Google Scholar
    • Export Citation
  • 38

    ZamagniEPatriarcaFNanniC. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood2011;118:59895995.

    • Search Google Scholar
    • Export Citation
  • 39

    NanniCZamagniECelliM. The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients. Clin Nucl Med2013;38:e7479.

    • Search Google Scholar
    • Export Citation
  • 40

    GreippPRLustJAO'FallonWM. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood1993;81:33823387.

    • Search Google Scholar
    • Export Citation
  • 41

    RajkumarSVDimopoulosMAPalumboA. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol2014;15:e538548.

    • Search Google Scholar
    • Export Citation
  • 42

    GreippPRSan MiguelJDurieBGM. International staging system for multiple myeloma. J Clin Oncol2005;23:34123420.

  • 43

    BladeJSamsonDReeceD. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol1998;102:11151123.

    • Search Google Scholar
    • Export Citation
  • 44

    RajkumarSV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol2011;86:5765.

  • 45

    PalumboARajkumarSVSan MiguelJF. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol2014;32:587600.

    • Search Google Scholar
    • Export Citation
  • 46

    KnowlingMAHarwoodARBergsagelDE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol1983;1:255262.

    • Search Google Scholar
    • Export Citation
  • 47

    DoresGMLandgrenOMcGlynnKA. Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol2009;144:8694.

    • Search Google Scholar
    • Export Citation
  • 48

    DimopoulosMAGoldsteinJFullerL. Curability of solitary bone plasmacytoma. J Clin Oncol1992;10:587590.

  • 49

    HuKYahalomJ. Radiotherapy in the management of plasma cell tumors. Oncology (Williston Park)2000;14:101108.

  • 50

    CreachKMFooteRLNeben-WittichMAKyleRA. Radiotherapy for extramedullary plasmacytoma of the head and neck. Int J Radiat Oncol Biol Phys2009;73:789794.

    • Search Google Scholar
    • Export Citation
  • 51

    Tournier–RangeardLLapeyreMGraff-CaillaudP. Radiotherapy for solitary extramedullary plasmacytoma in the head-and-neck region: A dose greater than 45 Gy to the target volume improves the local control. Int J Radiat Oncol Biol Phys2006;64:10131017.

    • Search Google Scholar
    • Export Citation
  • 52

    ReedVShahJMedeirosLJ. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer2011;117:44684474.

    • Search Google Scholar
    • Export Citation
  • 53

    FrassicaDAFrassicaFJSchrayMF. Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys1989;16:4348.

  • 54

    OzsahinMTsangRWPoortmansP. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys2006;64:210217.

    • Search Google Scholar
    • Export Citation
  • 55

    KnobelDZouhairATsangRW. Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer2006;6:118118.

    • Search Google Scholar
    • Export Citation
  • 56

    SasakiRYasudaKAbeE. Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy. Int J Radiat Oncol Biol Phys2012;82:626634.

    • Search Google Scholar
    • Export Citation
  • 57

    GerryDLentschEJ. Epidemiologic evidence of superior outcomes for extramedullary plasmacytoma of the head and neck. Otolaryngol Head Neck Surg2013;148:974981.

    • Search Google Scholar
    • Export Citation
  • 58

    KatoTTsukamotoENishiokaT. Early detection of bone marrow involvement in extramedullary plasmacytoma by whole-body F-18 FDG positron emission tomography. Clin Nucl Med2000;25:870873.

    • Search Google Scholar
    • Export Citation
  • 59

    NanniCRubelloDZamagniE. 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. In Vivo2008;22:513517.

  • 60

    The International Myeloma Working G. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology2003;121:749757.

    • Search Google Scholar
    • Export Citation
  • 61

    CesanaCKlersyCBarbaranoL. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol2002;20:16251634.

    • Search Google Scholar
    • Export Citation
  • 62

    MateosMVHernandezMTGiraldoP. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med2013;369:438447.

    • Search Google Scholar
    • Export Citation
  • 63

    DimopoulosMTerposEComenzoRL. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia2009.

    • Search Google Scholar
    • Export Citation
  • 64

    BredellaMASteinbachLCaputoG. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol2005;184:11991204.

    • Search Google Scholar
    • Export Citation
  • 65

    JadvarHContiPS. Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol2002;31:690694.

  • 66

    OrchardKBarringtonSBuscombeJ. Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma. Br J Haematol2002;117:133135.

    • Search Google Scholar
    • Export Citation
  • 67

    OcqueteauMOrfaoAAlmeidaJ. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol1998;152:16551665.

    • Search Google Scholar
    • Export Citation
  • 68

    Perez-PersonaEVidrialesMBMateoG. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood2007;110:25862592.

    • Search Google Scholar
    • Export Citation
  • 69

    QuachHRitchieDStewartAK. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia2010;24:2232.

  • 70

    Avet-LoiseauHLeleuXRousselM. Bortezomib plus dexamethasone induction improves outcome of patients With t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol2010.

    • Search Google Scholar
    • Export Citation
  • 71

    Chanan-KhanASonneveldPSchusterM. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol2008;26:47844790.

    • Search Google Scholar
    • Export Citation
  • 72

    MateosMHernandezJHernandezM. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood2006;108:21652172.

    • Search Google Scholar
    • Export Citation
  • 73

    RichardsonPSonneveldPSchusterM. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med2005;352:24872498.

  • 74

    VickreyEAllenSMehtaJSinghalS. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer2009;115:229232.

    • Search Google Scholar
    • Export Citation
  • 75

    MateosMV. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev2010;36Suppl 2:S2432.

  • 76

    HarousseauJLAttalMAvet-LoiseauH. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol2010;28:46214629.

    • Search Google Scholar
    • Export Citation
  • 77

    RichardsonPGBarlogieBBerensonJ. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med2003;348:26092617.

  • 78

    MoreauPAvet-LoiseauHFaconT. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood2011;118:57525758; quiz 5982.

    • Search Google Scholar
    • Export Citation
  • 79

    SonneveldPSchmidt-WolfIGvan der HoltB. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol2012;30:29462955.

    • Search Google Scholar
    • Export Citation
  • 80

    CavoMTacchettiPPatriarcaF. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet2010;376:20752085.

    • Search Google Scholar
    • Export Citation
  • 81

    KaufmanJLNookaAVranaM. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. Cancer2010;116:31433151.

    • Search Google Scholar
    • Export Citation
  • 82

    RosinolLOriolATeruelAI. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood2012;120:15891596.

    • Search Google Scholar
    • Export Citation
  • 83

    ReederCBReeceDEKukretiV. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia2009;23:13371341.

    • Search Google Scholar
    • Export Citation
  • 84

    EinseleHLiebischPLangerC. Velcade, intravenous cyclophosphamide and dexamethasone (VCD) induction for previously untreated multiple myeloma (German DSMM XIa Trial) [abstract]. Blood2009;114:Abstract 131.

    • Search Google Scholar
    • Export Citation
  • 85

    KumarSFlinnIRichardsonPG. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood2012;119:43754382.

    • Search Google Scholar
    • Export Citation
  • 86

    ReederCBReeceDEKukretiV. Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma. Br J Haematol2014;167:563565.

    • Search Google Scholar
    • Export Citation
  • 87

    ReederCBReeceDEKukretiV. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood2010;115:34163417.

    • Search Google Scholar
    • Export Citation
  • 88

    ZonderJACrowleyJHusseinMA. Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): Results of the randomized, double-blinded, placebo-controlled SWOG Trial S0232 [abstract]. Blood2007;110:Abstract 77.

    • Search Google Scholar
    • Export Citation
  • 89

    RajkumarSVJacobusSCallanderN. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood2007;110:Abstract 74.

    • Search Google Scholar
    • Export Citation
  • 90

    RajkumarSVJacobusSCallanderNS. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol2010;11:2937.

    • Search Google Scholar
    • Export Citation
  • 91

    GayFHaymanSRLacyMQ. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood2010;115:13431350.

    • Search Google Scholar
    • Export Citation
  • 92

    ZangariMTricotGPolavaramL. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol2010;28:132135.

    • Search Google Scholar
    • Export Citation
  • 93

    PalumboARajkumarSVDimopoulosMA. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia2008;22:414423.

    • Search Google Scholar
    • Export Citation
  • 94

    KumarSDispenzieriALacyMQ. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia2007;21:20352042.

    • Search Google Scholar
    • Export Citation
  • 95

    ParipatiHStewartAKCabouS. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia2008;22:12821284.

    • Search Google Scholar
    • Export Citation
  • 96

    KumarSGiraltSStadtmauerEA. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood2009;114:17291735.

    • Search Google Scholar
    • Export Citation
  • 97

    MarkTSternJFurstJR. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant2008;14:795798.

    • Search Google Scholar
    • Export Citation
  • 98

    NademaneeAPDiPersioJFMaziarzRT. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biol Blood Marrow Transplant2012;18:15641572.

    • Search Google Scholar
    • Export Citation
  • 99

    DuarteRFShawBEMarinP. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant2010.

    • Search Google Scholar
    • Export Citation
  • 100

    RichardsonPWellerELonialS. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood2010;116:679686.

    • Search Google Scholar
    • Export Citation
  • 101

    RousselMLauwers-CancesVRobillardN. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol2014;32:27122717.

    • Search Google Scholar
    • Export Citation
  • 102

    RajkumarSBloodEAVesoleD. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol2006;24:431436.

    • Search Google Scholar
    • Export Citation
  • 103

    RifkinRGregorySAMohrbacherAHusseinM. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer2006;106:848858.

    • Search Google Scholar
    • Export Citation
  • 104

    Arastu-KapurSAnderlJLKrausM. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res2011;17:27342743.

    • Search Google Scholar
    • Export Citation
  • 105

    KirkCJJiangJMuchamuelT. The selective proteasome inhibitor carfilzomib is well tolerated in experimental animals with dose intensive administration [abstract]. Blood2008;112:Abstract 2765.

    • Search Google Scholar
    • Export Citation
  • 106

    SiegelDSMartinTWangM. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood2012;120:28172825.

    • Search Google Scholar
    • Export Citation
  • 107

    VijRWangMKaufmanJL. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood2012;119:56615670.

    • Search Google Scholar
    • Export Citation
  • 108

    VijRWangMOrlowskiR. Initial results of PX-171-003, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma (MM) [abstract]. Blood2008;112:Abstract 865.

    • Search Google Scholar
    • Export Citation
  • 109

    JakubowiakAJDytfeldDGriffithKA. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood2012;120:18011809.

    • Search Google Scholar
    • Export Citation
  • 110

    DytfeldDJasielecJGriffithKA. Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica2014;99:e162164.

    • Search Google Scholar
    • Export Citation
  • 111

    KordeNZingoneAKwokM. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed Multiple Myeloma (MM) patients [abstract]. Blood2012;120:Abstract 732.

    • Search Google Scholar
    • Export Citation
  • 112

    KordeNZingoneAKwokM. Phase II Clinical and Correlative Study Of Carfilzomib Lenalidomide and Dexamethasone Followed By Lenalidomide Extended Dosing (CRD-R) Induces High Rates Of MRD Negativity In Newly Diagnosed Multiple Myeloma (MM) Patients [Abstract]. Vol. 122; 2013.

    • Search Google Scholar
    • Export Citation
  • 113

    GregoryWMRichardsMAMalpasJS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol1992;10:334342.

    • Search Google Scholar
    • Export Citation
  • 114

    PalumboABringhenSCaravitaT. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet2006;367:825831.

    • Search Google Scholar
    • Export Citation
  • 115

    PalumboABringhenSLiberatiAM. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood2008;112:31073114.

    • Search Google Scholar
    • Export Citation
  • 116

    FaconTMaryJYHulinC. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet2007;370:12091218.

    • Search Google Scholar
    • Export Citation
  • 117

    HulinCFaconTRodonP. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol2009;27:36643670.

    • Search Google Scholar
    • Export Citation
  • 118

    WijermansPSchaafsmaMTermorshuizenF. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol2010;28:31603166.

    • Search Google Scholar
    • Export Citation
  • 119

    KapoorPRajkumarSVDispenzieriA. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia2011;25:689696.

    • Search Google Scholar
    • Export Citation
  • 120

    PalumboAFalcoPCorradiniP. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. J Clin Oncol2007;25:44594465.

    • Search Google Scholar
    • Export Citation
  • 121

    RoyVStewartABergsagelP. Phase II study of melphalan, prednisone and lenalidomide combination for newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation [abstract]. Blood2008;112:Abstract 2769.

    • Search Google Scholar
    • Export Citation
  • 122

    PalumboAHajekRDelforgeM. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med2012;366:17591769.

  • 123

    StewartAJacobusSFonsecaF. E1A06: A phase III trial comparing melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma (MM) [Abstract]. J Clin Oncol2014;32: 5s_suppl:Abstract 8511.

    • Search Google Scholar
    • Export Citation
  • 124

    San MiguelJFSchlagRKhuagevaNK. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med2008;359:906917.

    • Search Google Scholar
    • Export Citation
  • 125

    San MiguelJFSchlagRKhuagevaNK. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol2013;31:448455.

    • Search Google Scholar
    • Export Citation
  • 126

    YehYChambersJGaugrisSJansenJ. Indirect comparison of the efficacy of melphalan-prednisone-bortezomib relative to melphalan-prednisone-thalidomide and melphalan-prednisone for the first line treatment of Multiple myeloma [abstract]. Blood2008;112:Abstract 2367.

    • Search Google Scholar
    • Export Citation
  • 127

    HarousseauJLPalumboARichardsonPG. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood2010;116:37433750.

    • Search Google Scholar
    • Export Citation
  • 128

    RajkumarSVJacobusSCallanderN. A randomized phase III trial of lenalidomide pus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the eastern Cooperative Oncology Group [abstract]. Blood2006;108:Abstract 799.

    • Search Google Scholar
    • Export Citation
  • 129

    BenboubkerLDimopoulosMADispenzieriA. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. New England Journal of Medicine2014;371:906917.

    • Search Google Scholar
    • Export Citation
  • 130

    AttalMLauwers-CancesVMaritG. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med2012;366:17821791.

    • Search Google Scholar
    • Export Citation
  • 131

    McCarthyPLOwzarKHofmeisterCC. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med2012;366:17701781.

  • 132

    UsmaniSSextonRHoeringA. Second malignancies in total therapy 3 trials for newly diagnosed multiple myeloma: Influence of lenalidomide versus thalidomide in maintenance phases [abstract]. Blood2011;118:Abstract 823.

    • Search Google Scholar
    • Export Citation
  • 133

    PalumboABringhenSKumarSK. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol2014;15:333342.

    • Search Google Scholar
    • Export Citation
  • 134

    NiesvizkyRFlinnIWRifkinR. Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: Results from all randomized patients in the community-based, phase 3b UPFRONT study [abstract]. Blood2011;118:Abstract 478.

    • Search Google Scholar
    • Export Citation
  • 135

    Jimenez ZepedaVHDugganPNeriPEBahlisNJ. Cyclophosphamide bortezomib and dexamethasone (CyBORD) is a feasible and active regimen for non-transplant Eligible Multiple Myeloma Patients. Vol. 124; 2014.

    • Search Google Scholar
    • Export Citation
  • 136

    BadrosABarlogieBMorrisC. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood2001;97:25742579.

    • Search Google Scholar
    • Export Citation
  • 137

    KrogerNSayerHGSchwerdtfegerR. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood2002;100:39193924.

    • Search Google Scholar
    • Export Citation
  • 138

    MoreauPFaconTAttalM. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood2002;99:731735.

    • Search Google Scholar
    • Export Citation
  • 139

    SomloGSpielbergerRFrankelP. Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma. Clin Cancer Res2011;17:174182.

    • Search Google Scholar
    • Export Citation
  • 140

    AttalMHarousseauJLStoppaAM. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med1996;335:9197.

    • Search Google Scholar
    • Export Citation
  • 141

    ChildJMorganGDaviesF. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med2003;348:18751883.

    • Search Google Scholar
    • Export Citation
  • 142

    BarlogieBKyleRAndersonK. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol2006;24:929936.

    • Search Google Scholar
    • Export Citation
  • 143

    FermandJKatsahianSDivineM. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol2005;23:92279233.

    • Search Google Scholar
    • Export Citation
  • 144

    CavoMTacchettiPPatriarcaF. Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma [abstract]Blood2008;112:Abstract 158.

    • Search Google Scholar
    • Export Citation
  • 145

    FermandJPRavaudPChevretS. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood1998;92:31313136.

    • Search Google Scholar
    • Export Citation
  • 146

    PalumboACavalloFGayF. Autologous Transplantation and Maintenance Therapy in Multiple Myeloma. New England Journal of Medicine2014;371:895905.

    • Search Google Scholar
    • Export Citation
  • 147

    PalumboACavalloFGayF. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med2014;371:895905.

  • 148

    CavoMTacchettiPPatriarcaF. A phase III study of double autotransplantation incorporating bortezomib–thalidomide–dexamethasone (VTD) or thalidomide–dexamethasone (TD) for multiple myeloma: superior clinical outcomes with VTD compared to TD [abstract]. Blood2009;114:Abstract 351.

    • Search Google Scholar
    • Export Citation
  • 149

    HahnTWingardJAndersonK. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant2003;9:437.

    • Search Google Scholar
    • Export Citation
  • 150

    KumarSLacyMQDispenzieriA. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant2004;34:161167.

    • Search Google Scholar
    • Export Citation
  • 151

    AttalMHarousseauJFaconT. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med2003;349:24952502.

    • Search Google Scholar
    • Export Citation
  • 152

    StadtmauerEA. Multiple myeloma, 2004--one or two transplants?N Engl J Med2003;349:25512553.

  • 153

    CavoMTosiPZamagniE. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol2007;25:24342441.

    • Search Google Scholar
    • Export Citation
  • 154

    SonneveldPvan der HoltBSegerenC. Intensive versus double intensive therapy in untreated multiple myeloma: Updated analysis of the randomized phase III study HOVON 24 MM [abstract]. Blood2004;104:Abstract 948.

    • Search Google Scholar
    • Export Citation
  • 155

    GoldschmidtH. Single vs double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 trialHaematologica2005;90(s1):Abstract 38

    • Search Google Scholar
    • Export Citation
  • 156

    BarlogieBAttalMCrowleyJ. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol2010;28:12091214.

    • Search Google Scholar
    • Export Citation
  • 157

    KyleRA. High-dose therapy in multiple myeloma and primary amyloidosis: an overview. Semin Oncol1999;26:7483.

  • 158

    KumarALoughranTAlsinaM. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol2003;4:293304.

    • Search Google Scholar
    • Export Citation
  • 159

    BrunoBRottaMPatriarcaF. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med2007;356:11101120.

  • 160

    RosinolLPerez-SimonJASuredaA. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood2008;112:35913593.

    • Search Google Scholar
    • Export Citation
  • 161

    GarbanFAttalMMichalletM. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood2006;107:34743480.

    • Search Google Scholar
    • Export Citation
  • 162

    KrishnanAPasquiniMCLoganB. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol2011;12:11951203.

    • Search Google Scholar
    • Export Citation
  • 163

    BjorkstrandBIacobelliSHegenbartU. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol2011;29:30163022.

    • Search Google Scholar
    • Export Citation
  • 164

    ZeiserRBertzHSpyridonidisA. Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. Bone Marrow Transplant2004;34:923928.

    • Search Google Scholar
    • Export Citation
  • 165

    van de DonkNWKrogerNHegenbartU. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant2006;37:11351141.

    • Search Google Scholar
    • Export Citation
  • 166

    LokhorstHMWuKVerdonckLF. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood2004;103:43624364.

    • Search Google Scholar
    • Export Citation
  • 167

    LokhorstHMSchattenbergACornelissenJJ. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol2000;18:30313037.

    • Search Google Scholar
    • Export Citation
  • 168

    LokhorstHMSchattenbergACornelissenJJ. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood1997;90:42064211.

    • Search Google Scholar
    • Export Citation
  • 169

    SalamaMNevillTMarcellusD. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant2000;26:11791184.

  • 170

    TricotGVesoleDHJagannathS. Graft-versus-myeloma effect: proof of principle. Blood1996;87:11961198.

  • 171

    AyukFShimoniANaglerA. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia2004;18:659662.

    • Search Google Scholar
    • Export Citation
  • 172

    BrinkerBTWallerEKLeongT. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer2006;106:21712180.

    • Search Google Scholar
    • Export Citation
  • 173

    AttalMHarousseauJLeyvrazS. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood2006;108:32893294.

    • Search Google Scholar
    • Export Citation
  • 174

    MorganGJJacksonGHDaviesFE. Maintenance thalidomide may improve progression free but not overall survival: Results from the Myeloma IX maintenance randomization [Abstract]. Blood2008;112:Abstract 565.

    • Search Google Scholar
    • Export Citation
  • 175

    BarlogieBTricotGAnaissieE. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med2006;354:10211030.

  • 176

    SpencerAPrinceMRobertsA. First analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) Trial of thalidomide and alternate day prednisolone following autologous stem cell transplantation (ASCT) for patients with multiple myeloma (ALLG MM6) [abstract]. Blood2006;108:Abstract 58.

    • Search Google Scholar
    • Export Citation
  • 177

    StewartAKTrudelSBahlisNJ. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood2013;121:15171523.

    • Search Google Scholar
    • Export Citation
  • 178

    KneppersEvan der HoltBKerstenMJ. Lenalidomide maintenance following non-myeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 trial. Blood2011.

    • Search Google Scholar
    • Export Citation
  • 179

    AlsinaMBeckerPSZhongX. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant2014;20:11831189.

    • Search Google Scholar
    • Export Citation
  • 180

    UsmaniSZSextonRHoeringA. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood2012;120:15971600.

    • Search Google Scholar
    • Export Citation
  • 181

    SinghPPKumarSKLaPlantBR. Lenalidomide maintenance therapy in multiple myeloma: a meta-analysis of randomized trials [asbtract]. American Society of Hematology Annual Meeting. 2013; Abstract 407.

    • Search Google Scholar
    • Export Citation
  • 182

    MellqvistUHGimsingPHjertnerO. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood2013;121:46474654.

    • Search Google Scholar
    • Export Citation
  • 183

    NiesvizkyRFlinnIWRifkinRM. Phase 3b UPFRONT study: safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple myeloma patients [abstract]. Blood2010;116:Abstract 619.

    • Search Google Scholar
    • Export Citation
  • 184

    BrowmanGPBergsagelDSicheriD. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol1995;13:23542360.

    • Search Google Scholar
    • Export Citation
  • 185

    FritzELudwigH. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol2000;11:14271436.

    • Search Google Scholar
    • Export Citation
  • 186

    ShustikCBelchARobinsonS. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol2007;136:203211.

    • Search Google Scholar
    • Export Citation
  • 187

    RosinnolLOriolATeruelAI. Maintenance therapy after stem-cell transplantation for multiple myeloma with bortezomib/thalidomide Vs. thalidomide Vs. alfa2b-interferon: Final results of a phase III pethema/GEM randomized trial [abstract]. Blood2012;120:Abstract 334.

    • Search Google Scholar
    • Export Citation
  • 188

    MateosMVOriolAMartinez-LopezJ. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood2012;120:25812588.

    • Search Google Scholar
    • Export Citation
  • 189

    BerensonJRLichtensteinAPorterL. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol1998;16:593602.

    • Search Google Scholar
    • Export Citation
  • 190

    BerensonJRLichtensteinAPorterL. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med1996;334:488493.

    • Search Google Scholar
    • Export Citation
  • 191

    MajorPLortholaryAHonJ. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol2001;19:558567.

    • Search Google Scholar
    • Export Citation
  • 192

    ZervasKVerrouETeleioudisZ. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol2006;134:620623.

    • Search Google Scholar
    • Export Citation
  • 193

    MorganGJDaviesFEGregoryWM. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet2010;376:19891999.

    • Search Google Scholar
    • Export Citation
  • 194

    BoydKMorganGDaviesF. Does zoledronic acid (ZOL) reduce skeletal-related events (SREs) and improve progression-free survival (PFS) in patients (Pts) with multiple myeloma (MM) with or without bone disease? MRC myeloma IX study results [abstract]. J Clin Oncol2011;29:Abstract 8010.

    • Search Google Scholar
    • Export Citation
  • 195

    MorganGJDaviesFGregoryW. Defining the biological subgroup of multiple myeloma patients which benefits maximally from the overall survival (OS) benefit associated with treatment with zoledronic acid (ZOL) [abstract]. J Clin Oncol2011;29:Abstract 8083.

    • Search Google Scholar
    • Export Citation
  • 196

    MorganGJDaviesFEGregoryWM. Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res2013;19:60306038.

    • Search Google Scholar
    • Export Citation
  • 197

    MhaskarRRedzepovicJWheatleyK. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev2012;5:CD003188.

  • 198

    MajorPPColemanRE. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program. Semin Oncol2001;28:1724.

    • Search Google Scholar
    • Export Citation
  • 199

    MajorPLortholaryAHonJ. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol2001;19:558567.

    • Search Google Scholar
    • Export Citation
  • 200

    PecherstorferMSteinhauerEURizzoliR. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Support Care Cancer2003;11:539547.

    • Search Google Scholar
    • Export Citation
  • 201

    LindsleyHTellerDNoonanB. Hyperviscosity syndrome in multiple myeloma. A reversible, concentration-dependent aggregation of the myeloma protein. Am J Med1973;54:682688.

    • Search Google Scholar
    • Export Citation
  • 202

    LudwigHFritzEKotzmannH. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med1990;322:16931699.

  • 203

    OsterborgABoogaertsMACiminoR. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood1996;87:26752682.

    • Search Google Scholar
    • Export Citation
  • 204

    IkhlaqueNSeshadriVKathulaSBaumannM. Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol2006;81:420422.

    • Search Google Scholar
    • Export Citation
  • 205

    BazRLiLKottke-MarchantK. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc2005;80: 15681574.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 280 279 27
PDF Downloads 45 45 0
EPUB Downloads 0 0 0